Table 3.
ΔSBPPostEx | ΔDBPPostEx | ΔSBPTraining | ΔDBPTraining | |
---|---|---|---|---|
Male gender | 0.20* | 0.07 | 0.17 | −0.07 |
Age | −0.01 | 0.12 | −0.18 | −0.03 |
Body mass index | 0.19* | 0.16 | 0.08 | −0.14 |
Waist-hip ratio | 0.05 | 0.03 | 0.07 | −0.14 |
Hypertension | −0.09 | −0.05 | −0.09 | −0.06 |
Current smoking | −0.12 | −0.06 | 0.10 | −0.05 |
CCS class ≥ 2 | 0.01 | 0.04 | 0.13 | −0.01 |
T2D | 0.20* | 0.20* | 0.11 | −0.04 |
History of myocardial infarction | 0.08 | 0.20* | 0.07 | 0.12 |
History of PCI or CABG | 0.08 | 0.10 | 0.09 | 0.10 |
LVEF | 0.00 | −0.03 | 0.05 | 0.12 |
LVMI | 0.06 | 0.07 | 0.09 | −0.14 |
E/E′ | −0.04 | −0.07 | 0.04 | −0.00 |
Syntax score | −0.01 | −0.02 | −0.08 | −0.30** |
MEDICATION | ||||
Oral antidiabetics | 0.17 | 0.19* | 0.07 | 0.01 |
Insulin | −0.04 | −0.10 | 0.13 | 0.02 |
Beta blockers | 0.09 | 0.13 | 0.02 | 0.12 |
ACEI or ARB | 0.01 | −0.02 | 0.05 | 0.04 |
Anticholesterol agents | −0.04 | 0.05 | −0.08 | 0.08 |
Anticoagulants | −0.17 | −0.07 | −0.09 | −0.01 |
Calcium antagonists | 0.06 | 0.06 | 0.06 | 0.06 |
Nitrates | 0.15 | 0.02 | 0.12 | −0.23* |
Diuretics | −0.11 | 0.01 | −0.01 | 0.05 |
LABORATORY ANALYSES | ||||
Fasting glucose | 0.15 | 0.12 | 0.06 | −0.07 |
HbA1c | 0.10 | 0.20* | −0.04 | −0.02 |
Insulin | 0.02 | 0.01 | 0.04 | 0.05 |
Total cholesterol | −0.17 | −0.08 | −0.06 | −0.06 |
LDL cholesterol | −0.20* | −0.09 | −0.02 | −0.03 |
HDL cholesterol | −0.10 | −0.12 | 0.00 | 0.06 |
Triglycerides | 0.11 | 0.21* | −0.08 | −0.07 |
hs-CRP | 0.04 | 0.00 | 0.06 | 0.08 |
Creatinine | 0.26 | 0.07 | −0.08 | −0.16 |
Albumin | −0.01 | 0.03 | −0.13 | −0.30** |
ACR | −0.06 | −0.02 | −0.15 | −0.31** |
SUPINE REST | ||||
SBP | −0.55*** | −0.38*** | −0.44*** | −0.28** |
DBP | −0.37*** | −0.54*** | −0.27** | −0.55*** |
HR | −0.09 | −0.15 | −0.10 | −0.14 |
LF | −0.12 | −0.09 | 0.01 | −0.09 |
HF | −0.07 | −0.08 | 0.09 | −0.01 |
LF/HF-ratio | −0.09 | −0.09 | −0.10 | −0.20* |
PASSIVE TILT | ||||
SBP | −0.38*** | −0.32** | −0.20* | −0.17 |
DBP | −0.32** | −0.35*** | −0.24* | −0.30** |
HR | −0.04 | −0.08 | −0.07 | −0.12 |
LF | −0.23* | −0.16 | −0.06 | −0.07 |
HF | −0.20* | −0.08 | 0.02 | 0.02 |
LF/HF-ratio | −0.06 | −0.20* | −0.11 | −0.24** |
EXERCISE TEST | ||||
EC, METs | 0.07 | −0.13 | 0.05 | −0.08 |
EC, % | −0.03 | −0.13 | −0.08 | −0.07 |
VO2peak, L·min−1 | 0.19* | −0.01 | 0.15 | −0.12 |
VO2peak, mL·kg−1·min−1 | 0.08 | −0.12 | 0.07 | −0.08 |
HRpeak | −0.10 | −0.23* | −0.10 | −0.08 |
SBPpeak | −0.06 | −0.17 | −0.11 | −0.13 |
DBPpeak | −0.18 | −0.10 | −0.22* | −0.02 |
ΔSBPPostEx | − | 0.56*** | 0.46*** | 0.21* |
ΔDBPPostEx | 0.56*** | − | 0.15 | 0.35*** |
Values are standardized coefficients (β) from univariate linear regression. CCS, Canadian Cardiovascular Society angina classification; T2D, type 2 diabetes; PCI, percutaneus coronary intervention; CABG, coronary artery by-pass grafting; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; E/E′, ratio of early transmitral flow velocity to early diastolic mitral annulus velocity; ACEI, angiotensin conversion enzymes inhibitor; ARB, angiotensin receptor blocker; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; ACR, albumin-creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LF, low frequency power of heart rate variability; HF, high frequency power of heart rate variability; EC, exercise capacity; VO2peak, peak oxygen consumption; PostEx, post-exercise.
p < 0.05,
p < 0.01,
p < 0.001.